DK1675954T3 - Nukleinsyrer anvendelige til at udløse tumorcelledødelighed - Google Patents

Nukleinsyrer anvendelige til at udløse tumorcelledødelighed

Info

Publication number
DK1675954T3
DK1675954T3 DK04817274.6T DK04817274T DK1675954T3 DK 1675954 T3 DK1675954 T3 DK 1675954T3 DK 04817274 T DK04817274 T DK 04817274T DK 1675954 T3 DK1675954 T3 DK 1675954T3
Authority
DK
Denmark
Prior art keywords
nucleic acids
tumor cell
acids useful
cell mortality
triggering tumor
Prior art date
Application number
DK04817274.6T
Other languages
English (en)
Inventor
Marie Dutreix
Jian-Sheng Sun
Original Assignee
Inst Curie
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Museum Nat D Histoire Naturelle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Curie, Inst Nat Sante Rech Med, Centre Nat Rech Scient, Museum Nat D Histoire Naturelle filed Critical Inst Curie
Application granted granted Critical
Publication of DK1675954T3 publication Critical patent/DK1675954T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
DK04817274.6T 2003-10-24 2004-10-25 Nukleinsyrer anvendelige til at udløse tumorcelledødelighed DK1675954T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03292666A EP1526177A1 (en) 2003-10-24 2003-10-24 Nucleic acids useful for triggering tumor cell lethality
PCT/EP2004/012857 WO2005040378A1 (en) 2003-10-24 2004-10-25 Nucleic acids useful for triggering tumor cell lethality

Publications (1)

Publication Number Publication Date
DK1675954T3 true DK1675954T3 (da) 2011-01-10

Family

ID=34384721

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04817274.6T DK1675954T3 (da) 2003-10-24 2004-10-25 Nukleinsyrer anvendelige til at udløse tumorcelledødelighed

Country Status (15)

Country Link
US (1) US7595302B2 (da)
EP (2) EP1526177A1 (da)
JP (2) JP4743789B2 (da)
CN (1) CN1871350B (da)
AT (1) ATE485375T1 (da)
AU (1) AU2004284228B2 (da)
CA (1) CA2542942C (da)
CY (1) CY1111060T1 (da)
DE (1) DE602004029699D1 (da)
DK (1) DK1675954T3 (da)
ES (1) ES2354359T3 (da)
PL (1) PL1675954T3 (da)
PT (1) PT1675954E (da)
SI (1) SI1675954T1 (da)
WO (1) WO2005040378A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476729B2 (en) * 2003-10-24 2009-01-13 Institut Curie Dbait and uses thereof
EP1944369A1 (en) * 2007-01-12 2008-07-16 The Centre National de la Recherche Scientifique Dbait and its standalone uses thereof
WO2009149921A2 (en) * 2008-06-11 2009-12-17 Bionucleon S.R.L. Inhibition of hrp-3 using modified oligonucleotides
AU2015202211B2 (en) * 2010-06-22 2016-09-01 Centre National De La Recherche Scientifique Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
TR201807294T4 (tr) 2010-06-22 2018-06-21 Centre Nat Rech Scient Nükleik asit konjugatları için endosomolitik ajanlar ile optimize edilmiş in vivo aktarım sistemi.
EP2527440A1 (en) 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
KR20160048212A (ko) * 2013-09-04 2016-05-03 씨에스아이알 유전자 발현을 침묵화시키기 위해 유전자 조절 인자들을 표적으로하는 부위-특이적인 뉴클레아제 단일 세포 분석법
AU2015280069B2 (en) * 2014-06-23 2021-08-12 The General Hospital Corporation Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
KR20220127360A (ko) * 2016-03-01 2022-09-19 옹쎄오 Ｄｂａｉｔ 분자의 전신 투여에 의한 암 치료법
WO2017186882A1 (en) 2016-04-29 2017-11-02 Onxeo A method of predicting a response to an anti-tumor treatment by means of signal interfering dna molecules
US10876116B2 (en) 2016-07-15 2020-12-29 The Board Of Regents Of The University Of Oklahoma Anti-ARID3a treatments for inflammatory disorders
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
CN108261548B (zh) * 2018-01-10 2020-04-10 浙江大学 一种纳米复合物及其制备方法和应用
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
AU2019256287B2 (en) 2018-04-17 2026-02-05 The General Hospital Corporation Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents
BR112021012066A2 (pt) 2018-12-21 2021-11-03 Onxeo Novas moléculas de ácido nucleico conjugadas e seus usos
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202210633A (zh) 2020-06-05 2022-03-16 法商昂席歐公司 用於治療癌症之dbait分子與kras抑制劑的組合
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
CA3240558A1 (en) 2021-12-16 2023-06-22 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001550A1 (en) * 1992-07-02 1994-01-20 Hybridon, Inc. Self-stabilized oligonucleotides as therapeutic agents
AU2018999A (en) * 1997-12-31 1999-07-19 Medical College Of Georgia Research Institute, Inc. Oligomers that bind to ku protein
EP0978561A1 (en) 1998-08-07 2000-02-09 Hoechst Marion Roussel Deutschland GmbH Antisense oligonucleotides for the inhibition of VEGF expression
US7060690B2 (en) * 2001-01-22 2006-06-13 Genta Incorporated Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof
AU2003213047A1 (en) 2002-02-13 2003-09-04 Medbridge, Inc. Protein carrier system for therapeutic oligonucleotides
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES

Also Published As

Publication number Publication date
CN1871350A (zh) 2006-11-29
US7595302B2 (en) 2009-09-29
CA2542942A1 (en) 2005-05-06
SI1675954T1 (sl) 2011-01-31
EP1675954A1 (en) 2006-07-05
PT1675954E (pt) 2010-12-27
JP2007510405A (ja) 2007-04-26
EP1526177A1 (en) 2005-04-27
WO2005040378A1 (en) 2005-05-06
JP5662822B2 (ja) 2015-02-04
CA2542942C (en) 2014-04-29
JP4743789B2 (ja) 2011-08-10
CN1871350B (zh) 2014-10-15
AU2004284228A1 (en) 2005-05-06
US20070197458A1 (en) 2007-08-23
JP2011126897A (ja) 2011-06-30
ES2354359T3 (es) 2011-03-14
DE602004029699D1 (de) 2010-12-02
CY1111060T1 (el) 2015-06-11
AU2004284228B2 (en) 2010-04-08
EP1675954B1 (en) 2010-10-20
ATE485375T1 (de) 2010-11-15
PL1675954T3 (pl) 2011-04-29

Similar Documents

Publication Publication Date Title
CY1111060T1 (el) Νουκλεϊκα οξεα χρησιμα για την πυροδοτηση της θνησιμοτητας κυτταρων ογκου
HRP20070012A2 (hr) Imunostimulatorski oligonukleotidni multimeri
EP2261248A3 (en) KDR peptides and vaccines comprising the same
EP2003196A3 (en) Compositions and methods for treating and diagnosing cancer
EP2730587A3 (en) Genes for enhancing nitrogen utilization efficiency in crop plants
DE60310202D1 (de) Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
WO2003064625A3 (en) Oligonucleotide compositions with enhanced efficiency
WO2008133647A3 (en) Antagonists of pcsk9
MY131964A (en) 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
AR049188A1 (es) Adenovirus quimericos para uso en el tratamiento del cancer
AR054526A1 (es) Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1)
AR051350A1 (es) Vacuna de glucoproteina mucinosa (muc-1)
AR039185A1 (es) Celulas hospedantes que tienen propiedades mejoradas de supervivencia celular y metodos para generar estas celulas
GB0418388D0 (en) Cell therapy
DK1664102T3 (da) Isoleret photoprotein mtclytin, samt dets anvendelse
WO2005007098A3 (en) Nucleic acid therapy to enhance cartilage repair
ATE454476T1 (de) 3'-modifizierte oligonukleotide mit pseudoisocytosin-nukleobasenderivaten sowie deren anwendungen als primer oder sonden
WO2003090778A3 (en) Dna vaccine combined with an inducer of tumor cell apoptosis
BR9913132A (pt) Nucleotìdeos da antitrombina e proteìnas do moscão
RU2003101855A (ru) Средство, нормализующее структуру и функции органов и тканей, стимулирующее репарирование повреждений, обладающее противовирусной активностью, и способ его получения
DK1507863T3 (da) Plasmidstabilisering in vivo
AU1248602A (en) Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids
WO2004011623A3 (en) Antisense modulation of ptpra expression
WO2002022557A3 (en) 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
TNSN06413A1 (en) Immunostimulatory oligonucleotide multimers